Table 1 Characteristics of included studies
Trials | Year | Phase | Treatment | Age | Sample | Sex | Histological types | Smoking status | STAGE | PD-L1 | Not resected | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Male | Female | Sq | N sq | Never | Current | Former | IB | IIA | IIB | IIIA | IIIB |  < 1% |  ≥ 1% | |||||||
NADIM II | 2023 | II | PNC | 65 (58–70) | 57 | 21 | 36 | 21 | 36 | 5 | 22 | 30 |  |  |  | 44 | 13 |  |  | 4 (7) |
PC | 63 (57–66) | 29 | 13 | 16 | 14 | 15 | 0 | 8 | 21 |  |  |  | 24 | 5 |  |  | 9 (45) | |||
CheckMate 77 T | 2023 | III | PNC | 66 (37–83) | 229 | 167 | 62 | 116 | 113 | 212 | 17 |  |  |  |  |  |  | 93 (40.6) | 128 (55.9) | 34 (14.8) |
NC | 66 (35–86) | 232 | 160 | 72 | 118 | 114 | 205 | 27 |  |  |  |  |  |  | 93 (40.1) | 128 (55.2) | 25 (10.8%) | |||
Neotorch | 2023 | III | PTRC | 62 (56–65) | 202 | 181 | 21 | 157 | 45 | 144 | 30 |  |  |  |  | 136 (67.3) | 65 (32.2) | 51 (25.3) | 133 (65.9) | 36 (18.8) |
PC | 61 (56–65) | 202 | 189 | 13 | 157 | 45 | 179 | 23 |  |  |  |  | 136 (67.3) | 64 (31.7) | 54 (26.7) | 132 (65.4) | 54 (26.7) | |||
AEGEAN | 2022 | III | PDC | 65 (30–88) | 366 | 252 | 114 | 169 | 196 | 271 | 95 |  |  | II | 104 (28.4) | 173 (47.3%) | 88 (24.0%) | 122 (33.3) | 244 (66.7) | 71 (19.4) |
NC | 65 (39–85) | 374 | 278 | 96 | 191 | 179 | 279 | 95 |  |  |  | 110 (29.4) | 165 (44.1%) | 98 (26.2%) | 125 (33.4) | 249 (66.6) | 72 (19.3) | |||
CheckMate 816 | 2022 | III | NNC | 64 (41–82) | 179 | 128 | 51 | 87 | 92 | 19 |  | 160 |  | IB or II | 65 (36.3) | 113 (63.1) |  | 78 (43.6) | 89 (49.7) | 28 (15.6) |
NC | 65 (34–84) | 179 | 127 | 52 | 95 | 84 | 20 |  | 158 |  |  | 62 (34.6) | 115 (64.2) |  | 77 (43.0) | 89 (49.7) | 37 (20.7) | |||
TD-FOREKNOW | 2023 | II | NCC | 61 (54–65) | 43 | 34 | 9 | 27 | 16 | 12 |  | 31 |  |  |  | 30 (69.8) | 13 (30.2) | 7 (16.3) | 16 (37.2) | 3 |
NC | 61 (54–65) | 45 | 40 | 5 | 32 | 13 | 8 |  | 37 |  |  |  | 36 (80.0) | 9 (20.0) | 8 (17.8) | 11 (24.4) | 3 | |||
KEYNOTE-671 | 2024 | III | PPC | 63 (26–83) | 397 | 279 | 118 | 171 | 226 | 54 | 96 | 247 |  |  | 118 (29.7%) | 217 (54.7%) | 62 (15.6%) | 138 (34.8%) | 259 (65.2%) | 5 (1.5%) |
NC | 64 (35–81) | 400 | 284 | 116 | 173 | 227 | 47 | 103 | 250 |  |  | 121 (30.3) | 225 (56.3%) | 54 (13.5%) | 151 (37.8%) | 249 (62.2%) | 15 (4.7%) | |||
CSLC0501 | 2018 | III | NC | 58 (26–75) | 97 | 79 | 18 | 50 | 47 | 28 | 69 |  | 30 (31.3) | 11 (11.5) | 26 (27.1) | 29 (30.2) |  |  |  | 15 (15.5) |
AC | 57 (31–76) | 101 | 80 | 21 | 52 | 49 | 30 | 71 |  | 34 (33.7) | 13 (12.9) | 30 (29.7) | 24 (23.8) |  |  |  | 0 | |||
IMpower010 | 2023 | III | AAC | 62 (55–67) | 507 | 337 | 170 | 179 | 328 | 114 | 76 | 317 | 65 (13%) | 147 (29%) | 90 (18%) | 205 (40%) |  | 210 (41%) | 248 |  |
AC | 62 (56–67) | 498 | 335 | 164 | 167 | 331 | 108 | 86 | 304 | 58 (12%) | 148 (30%) | 84 (17%) | 208 (42%) |  | 234 (47%) | 228 |  | |||
IFCT 0002 | 2013 | III | NC | 60 (34.5–75.2) | 267 | 215 | 52 | 115 | 152 |  |  |  | 127 (47.6%) | 10 (3.7%) | 79 (29.6%) |  |  |  |  |  |
PC | 61.7 (36.7–75.6) | 261 | 212 | 49 | 116 | 145 |  |  |  | 120 (46.0%) | 11 (4.2%) | 71 (27.2%) |  |  |  |  |  | |||
RATIONALE-315 | 2023 | III | PTSC | 62 (30–80) | 226 | 205 | 21 | 179 | 45 | 34 |  | 192 |  |  | 93 (41.2) | 132 (58.4) |  | 89 (39.4) | 130 (57.5) | 36 (15.9%) |
NC | 63 (36–78) | 227 | 205 | 22 | 175 | 50 | 39 |  | 188 |  |  | 93 (41.0) | 132 (58.1) |  | 84 (37.0) | 131 (57.7) | 54 (23.8%) | |||
KEYNOTE-091 | 2022 | III | APC | 65 (59–70) | 590 | 401 | 189 | 192 | 398 | 87 | 75 | 428 | 84 (14%) | II | 177 (30%) | 329 (56%) |  | 233 (39%) | 257 (61%) |  |
AC | 65 (59–70) | 587 | 403 | 184 | 224 | 363 | 66 | 90 | 431 | 85 (14%) |  | 162 (28%) | 338 (58%) |  | 232 (40%) | 253 (60%) |  | |||